Cardiac monitoring during adjuvant trastuzumab-based chemotherapy among older patients with breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 19, 2015, Pages 2176-2183

  Chavez MacGregor, Mariana ^a   Niu, Jiangong ^a   Zhang, Ning ^a   Elting, Linda S ^a   Smith, Benjamin D ^a   Banchs, Jose ^a   Hortobagyi, Gabriel N ^a   Giordano, Sharon H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIAC MONITORING; COMORBIDITY; DATA BASE; ECHOCARDIOGRAPHY; FEMALE; GERIATRIC DISORDER; HEALTHCARE COMMON PROCEDURE CODING SYSTEM; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT MONITORING; PHYSICIAN; PRIORITY JOURNAL; VERY ELDERLY; ADVERSE EFFECTS; BREAST NEOPLASMS; CANCER REGISTRY; CANCER STAGING; CHEMICALLY INDUCED; DRUG MONITORING; HEART DISEASE; HEART FUNCTION TEST; PATHOLOGY; RETROSPECTIVE STUDY; RISK FACTOR; UNITED STATES;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; DRUG MONITORING; FEMALE; HEART DISEASES; HEART FUNCTION TESTS; HUMANS; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; SEER PROGRAM; TEXAS;

EID: 84937134040     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.58.9465     Document Type: Article

References (39)

1. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
2. Slamon D, Eiermann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
3. Viani GA, Afonso SL, Stefano EJ, et al: Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 7:153, 2007
4. Joensuu H, Bono P, Kataja V, et al: Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: Final results of the FinHer Trial. J Clin Oncol 27:5685-5692, 2009
5. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
6. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
8. Romond EH, Jeong JH, Rastogi P, et al: Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30:3792-3799, 2012
9. Spielmann M, Roché H, Delozier T, et al: Trastuzumab for patients with axillary-node-positive breast cancer: Results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129-6134, 2009
10. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005
11. de Azambuja E, Procter MJ, van Veldhuisen DJ, et al: Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol 32:2159-2165, 2014
12. Bowles EJ, Wellman R, Feigelson HS, et al: Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Natl Cancer Inst 104:1293-1305, 2012
13. Chen J, Long JB, Hurria A, et al: Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60:2504-2512, 2012
14. Du XL, Xia R, Burau K, et al: Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med Oncol 28:S80-S90, 2011
15. McArthur HL, Chia S: Cardiotoxicity of trastuzumab in clinical practice. N Engl J Med 357:94-95, 2007
16. Tarantini L, Cioffi G, Gori S, et al: Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 18:113-119, 2012
17. Tarantini L, Gori S, Faggiano P, et al: Adjuvant trastuzumab cardiotoxicity in patients over 60 years of age with early breast cancer: A multicenter cohort analysis. Ann Oncol 23:3058-3063, 2012
18. Chavez-MacGregor M, Zhang N, Buchholz TA, et al: Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31:4222-4228, 2013
19. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 3.2014
20. Howlander N, Noone AM, Krapcho M, et al: (eds): SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD. Based on November 2013 SEER data submission, posted to the SEER web site, April 2014. http://seer.cancer.gov/csr/1975-2011/
21. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
22. Slamon D, Eiermann W, Robert N, et al: BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006 (abstr 52)
23. Charlson ME, Pompei P, Ales KL, et al: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40:373-383, 1987
24. Romano PS, Roos LL, Jollis JG: Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 46:1075-1079, 1993; discussion 1081-1090
25. Hanley JA, Negassa A, Edwardes MD, et al: Statistical analysis of correlated data using generalized estimating equations: An orientation. Am J Epidemiol 157:364-375, 2003
26. Wu S, Crespi CM, Wong WK: Comparison of methods for estimating the intraclass correlation coefficient for binary responses in cancer prevention cluster randomized trials. Contemp Clin Trials 33:869-880, 2012
27. Shahinian VB, Kuo YF, Freeman JL, et al: Determinants of androgen deprivation therapy use for prostate cancer: Role of the urologist. J Natl Cancer Inst 98:839-845, 2006
28. Snijders TAB, Bosker RJ: Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling. Thousand Oaks, CA, SAGE Publications, 2011
29. Hoffman KE, Niu J, Shen Y, et al: Physician variation in management of low-risk prostate cancer: A population-based cohort study. JAMA Intern Med 174:1450-1459, 2014
30. Mackey JR, Clemons M, Côté MA, et al: Cardiac management during adjuvant trastuzumab therapy: Recommendations of the Canadian Trastuzumab Working Group. Curr Oncol 15:24-35, 2008
31. Jones AL, Barlow M, Barrett-Lee PJ, et al: Management of cardiac health in trastuzumab-treated patients with breast cancer: Updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 100:684-692, 2009
32. Genentech: Package insert for Herceptin (Trastuzumab). http://www.accessdata.fda.gov/drugsatfda-docs/label/2000/trasgen020900lb.htm
33. Ng D FI, Khong H, Earle C, et al: Cardiac monitoring during adjuvant trastuzumab for breast cancer. Cancer Res 72:471s, 2012 (abstract P-5-18-14)
34. Chin-Yee NJ, Yan A, Tomlinson GA, et al: Impact of center case volume on cardiotoxicity during adjuvant trastuzumab in breast cancer. J Clin Oncol 31, 2013 (suppl 15s; abstr 6625)
35. Tjan-Heijnen VC, Seferina SC, De Boer M, et al: Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily Dutch practice. J Clin Oncol 31, 2013 (suppl 15s; abstr e11558)
36. Takada M, Ishiguro H, Nagai S, et al: Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: A multicenter retrospective observational study (JBCRG-C03 study). Breast Cancer Res Treat 145:143-153, 2014
37. Vaz-Luis I, Keating NL, Lin NU, et al: Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: A population-based study. J Clin Oncol 32:927-934, 2014
38. Kadakia A, Rajan SS, Abughosh S, et al: CMF-regimen preferred as first-course chemotherapy for older and sicker women with breast cancer: Findings from a SEER-Medicare-based population study. Am J Clin Oncol 38:165-173, 2015
39. Gujral DM, Lloyd G, Bhattacharyya S: Cardiac toxicity monitoring for HER2-positive breast cancer patients undergoing trastuzumab therapy: Are we doing enough? Clin Oncol (R Coll Radiol) 25:446-447, 2013